<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00342563</url>
  </required_header>
  <id_info>
    <org_study_id>26364</org_study_id>
    <nct_id>NCT00342563</nct_id>
  </id_info>
  <brief_title>Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients</brief_title>
  <official_title>Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study will be to evaluate the efficacy of mecamylamine in reducing alcohol
      consumption in smoking and non-smoking alcohol dependent patients.

      We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption
      than placebo. We further hypothesize that mecamylamine will be effective in reducing both
      alcohol consumption and smoking in a subset of alcoholics who also smoke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RESEARCH PLAN: Although there are two FDA approved medications for the treatment of alcohol
      dependence (naltrexone and disulfiram), the robust efficacy of both compounds in reducing
      alcohol consumption has recently been called into question. Given the high rates of alcohol
      dependence among the general population, development and testing of novel medications is of
      great importance.

      Mecamylamine, a noncompetitive NACh receptor antagonist has been shown to be useful in
      smoking cessation when used in combination with transdermal nicotine. To our knowledge,
      clinical studies examining the effectiveness of mecamylamine in alcoholism have not been
      conducted. However, there is evidence from animal research that mecamylamine can block the
      effects of alcohol. Infusion of mecamylamine into the ventral tegmental area antagonized
      ethanol-induced dopamine release in rats. More importantly, mecamylamine decreased alcohol
      intake and preference in alcohol-preferring rats. In two studies with healthy volunteers
      mecamylamine was effective in attenuating the euphoric effects of alcohol and reducing the
      craving for alcohol.

      This is the first study designed to test the clinical efficacy of mecamylamine in a sample of
      alcohol dependent patients who either do or do not smoke.

      For the proposed project we will recruit 60 treatment seeking patients between the ages of 18
      and 60 who meet criteria for alcohol dependence and may or may not smoke. Patients will be
      randomized into two groups (30 patients in each group): one dose of mecamylamine (10mg) or
      placebo in a double-blind fashion for 12 weeks. Patients will be asked to come for follow up
      3 months after completing the study. Patients will be excluded if they: take medications
      thought to influence drinking behavior, have a significant underlying medical conditions,
      such as cerebral, renal, thyroid, hepatic or cardiac pathology; have a history of glaucoma,
      prostatic hypertrophy, urethral obstruction, cerebral arteriosclerosis, pyloric stenosis, or
      a history of hypersensitivity to mecamylamine; or meet current criteria for Bipolar
      Disorders, Schizophrenia and Schizophrenia-type Disorders, Major Depression or Posttraumatic
      Stress Disorders (PTSD). Females who are pregnant or lactating will also be excluded.

      We hypothesize that mecamylamine will result in a greater reduction of alcohol consumption
      than placebo among the alcohol dependent patients. We further hypothesize that mecamylamine
      will be effective in reducing both alcohol consumption and smoking in a subgroup of
      alcoholics who also smoke.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Heavy Drinking Days During Active Treatment Phase</measure>
    <time_frame>12 weeks</time_frame>
    <description>Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) average during 90 days of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report Weekly Smoking Craving</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire of smoking urges (QSU). It has 32 questions that range from 1 to 7, there are 8 questions per sub-scale. The total range is 32 to 224. Each sub-scale ranges from 8- 56, with a higher score indicating higher craving.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report Average Number of Cigarettes Per Day</measure>
    <time_frame>12 weeks</time_frame>
    <description>self-report from only the smoking population for cigarettes per day</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Mecamylamine- Smoker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Smoker</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mecamylamine- Non-Smoker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Non-Smoker</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mecamylamine</intervention_name>
    <description>mecamylamine 10mg/day</description>
    <arm_group_label>Mecamylamine- Smoker</arm_group_label>
    <arm_group_label>Mecamylamine- Non-Smoker</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo-Smoker</arm_group_label>
    <arm_group_label>Placebo-Non-Smoker</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  individuals with DSM-IV diagnosis of alcohol dependence

          -  smokers and non-smokers

          -  patients who do not require psychotropic medication for the management of their
             psychiatric symptoms

          -  individuals with a history of substance dependence (other than alcohol and tobacco)
             but have not met criteria for substance dependence in the past 30 days

          -  women with acceptable method of contraception

        Exclusion Criteria:

          -  pregnant women

          -  medications thought to influence drinking behavior including: acamprosate, disulfiram,
             naltrexone and ondansetron

          -  underlying medical conditions

          -  history of glaucoma, prostatic hypertrophy, urethral obstruction, cerebral
             arteriosclerosis, pyloric stenosis, or a history of hypersensitivity to mecamylamine

          -  DSM-IV diagnosis of bipolar disorder, schizophrenia, and schizophrenia-type disorders

          -  unstable medical conditions

          -  patients who require psychotropic medication for the management of an active
             psychiatric disorder

          -  patients on pharmacological treatment for alcohol and/or nicotine dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismene Petrakis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2006</study_first_submitted>
  <study_first_submitted_qc>June 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2006</study_first_posted>
  <results_first_submitted>October 24, 2016</results_first_submitted>
  <results_first_submitted_qc>April 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mecamylamine</keyword>
  <keyword>treatment</keyword>
  <keyword>alcohol dependence</keyword>
  <keyword>smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Mecamylamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mecamylamine- Smoker</title>
          <description>mecamylamine: mecamylamine 10mg/day</description>
        </group>
        <group group_id="P2">
          <title>Mecamylamine Non-Smoker</title>
        </group>
        <group group_id="P3">
          <title>Placebo Smoker</title>
        </group>
        <group group_id="P4">
          <title>Placebo Non-Smoker</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One hundred and thirty six (136) individuals were randomized in this study with equal number of participants assigned to treatment (n=68) and placebo (n=68) groups. Randomization was stratified by gender and smoking status.</population>
      <group_list>
        <group group_id="B1">
          <title>Mecamylamine-Smoker</title>
          <description>mecamylamine: mecamylamine 10mg/day</description>
        </group>
        <group group_id="B2">
          <title>Mecamylamine-Non-Smoker</title>
        </group>
        <group group_id="B3">
          <title>Placebo-Smoker</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="B4">
          <title>Placebo- Non-Smoker</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="28"/>
            <count group_id="B5" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.83" spread="8.42"/>
                    <measurement group_id="B2" value="50.93" spread="9.55"/>
                    <measurement group_id="B3" value="47.28" spread="8.69"/>
                    <measurement group_id="B4" value="51.14" spread="10.28"/>
                    <measurement group_id="B5" value="48.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Veteran Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Veteran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Veteran</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Heavy Drinking Days During Active Treatment Phase</title>
        <description>Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) average during 90 days of treatment.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mecamylamine- Smokers</title>
            <description>mecamylamine: mecamylamine 10mg/day</description>
          </group>
          <group group_id="O2">
            <title>Mecamylamine- Non-Smoker</title>
            <description>mecamylamine: mecamylamine 10mg/day</description>
          </group>
          <group group_id="O3">
            <title>Placebo-Smoker</title>
            <description>Placebo</description>
          </group>
          <group group_id="O4">
            <title>Placebo- Non-Smoker</title>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days During Active Treatment Phase</title>
          <description>Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) average during 90 days of treatment.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.75" spread="4.33"/>
                    <measurement group_id="O2" value="24.28" spread="5.30"/>
                    <measurement group_id="O3" value="20.51" spread="4.57"/>
                    <measurement group_id="O4" value="21.78" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)</title>
        <description>The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48.</description>
        <time_frame>12 weeks</time_frame>
        <population>Scores presented are total, and then by subgroup.</population>
        <group_list>
          <group group_id="O1">
            <title>Mecamylamine</title>
            <description>mecamylamine: mecamylamine 10mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)</title>
          <description>The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48.</description>
          <population>Scores presented are total, and then by subgroup.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.772" spread="1.165"/>
                    <measurement group_id="O2" value="8.032" spread="1.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Smokers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.575" spread="1.851"/>
                    <measurement group_id="O2" value="8.352" spread="1.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Smokers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.969" spread="1.713"/>
                    <measurement group_id="O2" value="7.712" spread="1.563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-report Weekly Smoking Craving</title>
        <description>Questionnaire of smoking urges (QSU). It has 32 questions that range from 1 to 7, there are 8 questions per sub-scale. The total range is 32 to 224. Each sub-scale ranges from 8- 56, with a higher score indicating higher craving.</description>
        <time_frame>12 weeks</time_frame>
        <population>Smokers only</population>
        <group_list>
          <group group_id="O1">
            <title>Mecamylamine</title>
            <description>mecamylamine: mecamylamine 10mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Self-report Weekly Smoking Craving</title>
          <description>Questionnaire of smoking urges (QSU). It has 32 questions that range from 1 to 7, there are 8 questions per sub-scale. The total range is 32 to 224. Each sub-scale ranges from 8- 56, with a higher score indicating higher craving.</description>
          <population>Smokers only</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Desire to Smoke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.741" spread="1.311"/>
                    <measurement group_id="O2" value="28.047" spread="1.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anticipation of a positive outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.705" spread="1.718"/>
                    <measurement group_id="O2" value="28.273" spread="1.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relief</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.557" spread="1.604"/>
                    <measurement group_id="O2" value="24.032" spread="1.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intention to smoke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.108" spread="1.793"/>
                    <measurement group_id="O2" value="32.549" spread="1.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-report Average Number of Cigarettes Per Day</title>
        <description>self-report from only the smoking population for cigarettes per day</description>
        <time_frame>12 weeks</time_frame>
        <population>only smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Mecamylamine</title>
            <description>mecamylamine: mecamylamine 10mg/day</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Self-report Average Number of Cigarettes Per Day</title>
          <description>self-report from only the smoking population for cigarettes per day</description>
          <population>only smokers</population>
          <units>cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.055" spread="1.163"/>
                    <measurement group_id="O2" value="10.681" spread="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Adverse events were screened for on a weekly basis. Symptom data were clustered into the following categories: gastrointestinal (GI), central nervous system (CNS), neurological (NE), musculoskeletal (MS), skin, ophthalmological (OPTH), cardio/pulmonary (CAR), and genito-urinary (GU).</desc>
      <group_list>
        <group group_id="E1">
          <title>Mecamylamine Smoker</title>
          <description>mecamylamine: mecamylamine 10mg/day</description>
        </group>
        <group group_id="E2">
          <title>Mecamylamine Non-Smoker</title>
          <description>mecamylamine: mecamylamine 10mg/day</description>
        </group>
        <group group_id="E3">
          <title>Placebo Smoker</title>
          <description>Placebo: Placebo</description>
        </group>
        <group group_id="E4">
          <title>Placebo Non-Smoker</title>
          <description>Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Psychotic Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>central nervous system symptoms</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elizabeth Ralevski</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>+1 203-932-5711 ext x4282</phone>
      <email>elizabeth.ralevski@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

